Comparative Pharmacology
Head-to-head clinical analysis: ISIBLOOM versus NORINYL 1 50 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISIBLOOM versus NORINYL 1 50 28 DAY.
ISIBLOOM vs NORINYL 1+50 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ISIBLOOM is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby enhancing serotonin levels in the synaptic cleft.
Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.
Adults: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks if tolerated. Maximum dose: 600 mg once daily.
One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults, permitting twice-daily dosing; prolonged to 24–30 hours in severe renal impairment (CrCl <30 mL/min).
Norethindrone: ~8-11 hours; Mestranol: 24 hours (prodrug, ethinyl estradiol half-life ~13-27 hours).
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 35%; minor metabolism (<5%) via CYP3A4.
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive